Financial Data and Key Metrics Changes - The company launched its product in early October after receiving approval in late July, and within the first four weeks, it recorded 5,000 scripts written by 2,500 doctors, indicating strong initial interest and confidence in the product [27][29]. - Awareness of the product among doctors exceeded 90%, which is considered exceptional for a new product [12]. Business Line Data and Key Metrics Changes - The company has fully operational e-pharmacy and retail pharmacy channels, allowing consumers to order the product online or pick it up at local pharmacies [10]. - The company is seeing early signs of refill orders, although it is too early to provide specific metrics on refill rates [11][14]. Market Data and Key Metrics Changes - The product is skewing towards a slightly female demographic, with 60% of orders coming from women, primarily in the 45-55 age group [18][67]. - The company is targeting urban areas, which aligns with its initial market strategy [67]. Company Strategy and Development Direction - The company is focused on maximizing the launch of its product, with plans to turn on direct-to-consumer (DTC) marketing in Q1, which is expected to drive new patient starts [15][78]. - The company is also exploring international markets, with NDA submissions in South Korea and partnerships in Greater China and Canada [36][38]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the product's performance based on positive feedback from doctors and patients, noting that the product works effectively for nearly all patients [3][5]. - The company is aware of the competitive landscape, particularly regarding other products like Vuity, and believes its product has superior efficacy and a better market position [45][49]. Other Important Information - The company has established a strong marketing strategy, including the hiring of a celebrity spokesperson, Sarah Jessica Parker, to enhance brand awareness [19][78]. - The product is priced at $79 per month, which was determined through extensive market research to optimize revenue [69]. Q&A Session Summary Question: How is the launch going and what are the early metrics? - The company reported 5,000 scripts and 2,500 doctors writing prescriptions within the first four weeks, indicating strong interest [27][29]. Question: What is the strategy for direct-to-consumer marketing? - The company plans to launch DTC in Q1, focusing on building awareness and confidence among doctors before driving consumer demand [15][78]. Question: How does the company view its competitors? - The company sees itself as a category of one, with its product being the only pupil-selective miotic, and believes it has a significant advantage over competitors like Vuity [45][49].